Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal‑type breast cancer

Suzuki,Takafumi; Yamagishi,Yoji; Einama,Takahiro; Koiwai,Tomomi; Yamasaki,Tamio; Fukumura‑koga,Makiko; Ishibashi,Yusuke; Takihata,Yasuhiro; Shiraishi,Takehiro; Miyata,Yoichi; Iwasaki,Toshimitsu; Shinto,Eiji; Sato,Kimiya; Ueno,Hideki; Yamamoto,Junji; Kishi,Yoji; Tsuda,Hitoshi

doi:10.3892/ol.2020.12055

Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal‑type breast cancer

Authors:
- Takafumi Suzuki
- Yoji Yamagishi
- Takahiro Einama
- Tomomi Koiwai
- Tamio Yamasaki
- Makiko Fukumura‑koga
- Yusuke Ishibashi
- Yasuhiro Takihata
- Takehiro Shiraishi
- Yoichi Miyata
- Toshimitsu Iwasaki
- Eiji Shinto
- Kimiya Sato
- Hideki Ueno
- Junji Yamamoto
- Yoji Kishi
- Hitoshi Tsuda
View Affiliations

Affiliations: Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan, Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan
Published online on: September 3, 2020 https://doi.org/10.3892/ol.2020.12055
Article Number: 193
Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesothelin is expressed in various types of malignant tumors. The present study immunohistochemically investigated mesothelin expression and its clinicopathological significance in each subtype of breast cancer, with special reference to its cellular localization, in particular, membrane mesothelin expression. Using tissue specimens from 482 patients with breast cancer, immunohistochemistry was used to study mesothelin expression and help classify its localization as membrane or cytoplasmic expression. Mesothelin expression was detected in 77 (16.0%) cases and was the highest in triple‑negative breast cancer (31/75; 41.3%), followed by human epithelial growth factor receptor type 2 type (6/33, 18.2%) and luminal type (36/374; 9.6%). Among the 482 cases, membrane mesothelin expression was detected in 73 cases and was significantly associated with a negative hormone receptor status, higher Ki‑67 labeling index, nuclear grade 3 and a lower relapse‑free survival rate. Cytoplasmic mesothelin expression was not significantly associated with a lower relapse‑free survival rate (P=0.058). In the 343 cases of luminal type, the membrane mesothelin expression‑positive group had significantly worse prognosis than the membrane mesothelin‑expression‑negative group (P=0.042). There was no significant difference in the relapse‑free survival rate according to the membrane mesothelin expression status in the triple‑negative type and other types. It was suggested that membrane mesothelin expression in luminal type breast cancer is associated with a lower rate of relapse‑free survival.

View Figures

View References

1	Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 50:373–381. 1992. View Article : Google Scholar : PubMed/NCBI
2	Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
3	Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
4	Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, et al: Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
6	Hassan R, Bera T and Pastan I: Mesothelin: A new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
7	Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen S and Yao Q: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 7:286–296. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shiraishi T, Shinto E, Mochizuki S, Tsuda H, Kajiwara Y, Okamoto K, Einama T, Hase K and Ueno H: Mesothelin expression has prognostic value in stage II/III colorectal cancer. Virchows Arch. 474:297–307. 2019. View Article : Google Scholar : PubMed/NCBI
9	Einama T, Homma S, Kamachi H, Kawamat F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
10	Shiraishi T, Shinto E, Nearchou IP, Tsuda H, Kajiwara Y, Einama T, Caie PD, Kishi Y and Ueno H: Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays. Virchows Arch. Feb 27–2020.(Epub ahead of print). doi: 10.1007/s00428-020-02775-y. View Article : Google Scholar : PubMed/NCBI
11	Wang L, Niu Z, Zhang L, Liu X, Wang X, Li F and Wang Y: Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res. 40:909–916. 2012. View Article : Google Scholar : PubMed/NCBI
12	Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M and Gonzalez-Angulo AM: Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 13:378–384. 2013. View Article : Google Scholar : PubMed/NCBI
13	Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A and Yildiz Y: Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. Biomed Pharmacother. 70:190–195. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH and Zhang PJ: Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 133:799–804. 2012. View Article : Google Scholar : PubMed/NCBI
15	Tsuda H, Akiyama F, Kurosumi M, Sakamoto G and Watanabe T: Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) pathology section. Jpn J Clin Oncol. 28:486–491. 1998. View Article : Google Scholar : PubMed/NCBI
16	Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et al: Assessment of Ki67 in breast cancer: Recommendations from the international Ki67 in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
17	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
18	Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, et al: De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 30:11812019. View Article : Google Scholar : PubMed/NCBI
19	Wang M, Li A, Sun G, Mbuagbaw L, Reid S, Lovrics PJ and Thabane L: Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: A protocol for a systematic review. Syst Rev. 5:1332016. View Article : Google Scholar : PubMed/NCBI
20	Tan AR and Swain SM: Therapeutic strategies for triple-negative breast cancer. Cancer J. 14:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A and Todo S: Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 41:2109–2118. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y and Taketomi A: The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. Oncotarget. 9:33844–33852. 2018. View Article : Google Scholar : PubMed/NCBI
23	Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C and Nakagawa K: Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 33:380–388. 2015. View Article : Google Scholar : PubMed/NCBI